Oncotarget

Corrections:

Correction: Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance

PDF  |  How to cite

Oncotarget. 2018; 9:32403-32403. https://doi.org/10.18632/oncotarget.26020

Metrics: PDF 1116 views  |   ?  

Man Kit Siu1,2,*, Wassim Abou-Kheir3,*, Juan Juan Yin4,*, Yung-Sheng Chang1, Ben Barrett4, Florent Suau4, Orla Casey4, Wei-Yu Chen5, Lei Fang4, Paul Hynes4, Yao-Yu Hsieh1,6,9,Yen-Nien Liu1,7, Jiaoti Huang8 and Kathleen Kelly4

1 Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
2 Department of Anesthesiology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
3 Department of Anatomy, Cell Biology and Physiological Sciences Faculty of Medicine, American University of Beirut, Beirut, Lebanon
4 Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
5 Department of Pathology, Wan Fang Hospital, College of Medicine, Taipei Medical University, Taipei, Taiwan
6 Division of Hematology and Oncology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan
7 Center of Excellence for Cancer Research, Wan Fang Hospital, College of Medicine, Taipei Medical University, Taipei, Taiwan
8 Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, USA
9 Department of Internal Medicine, Division of Hematology and Oncology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
* These authors contributed equally to this work

Published: August 17, 2018

This article has been corrected: The author affiliation is given below:

Yao-Yu Hsieh1,6,9

9 Department of Internal Medicine, Division of Hematology and Oncology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

Original article: Oncotarget. 2014; 5:3770-3784. DOI: https://doi.org/10.18632/oncotarget.1994.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26020